Auro Laboratories Ltd

Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 22 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced notable shifts in its valuation parameters, prompting a reassessment of its price attractiveness. With its price-to-earnings (P/E) ratio moving from very expensive to expensive territory and a recent downgrade in its Mojo Grade to Strong Sell, investors are urged to carefully analyse the evolving fundamentals and relative valuation metrics against peers and historical benchmarks.

Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 11 August 2026, providing investors with the most up-to-date insight into the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook.

Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 8 July 2026, reflecting a marked deterioration in its technical outlook and persistent fundamental challenges. Despite a positive quarterly financial performance, the company’s valuation, financial trends, and technical indicators have collectively triggered this reassessment, signalling caution for investors in this micro-cap pharmaceutical player.

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Auro Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 03 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 June 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Auro Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its quality grading downgraded from Hold to Sell, reflecting a notable deterioration in its business fundamentals. Key financial parameters such as return on equity (ROE), return on capital employed (ROCE), and growth metrics have weakened, raising concerns about the company’s operational efficiency and financial health amid a challenging industry backdrop.

Auro Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a positive financial performance for the quarter ended March 2026, with robust revenue growth and improved profitability. However, certain operational metrics indicate emerging challenges, prompting a reassessment of its investment grade from Buy to Hold by MarketsMOJO as of 2 March 2026.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 Mar 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 31 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall market stance.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 Mar 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Auro Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 Mar 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing.